Relmada Therapeutics, Inc. - Enterprise Value

The Enterprise Value as of July 2026 (TTM) for Relmada Therapeutics, Inc. (RLMD) is 529.36M

According to Relmada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 529.36M. This represents a change of 111.11% compared to the average of 250.75M of the last 4 quarters.

Relmada Therapeutics, Inc. (RLMD) Historical Enterprise Value (quarterly & annually)

How has RLMD Enterprise Value performed in the past?

The mean historical Enterprise Value of Relmada Therapeutics, Inc. over the last ten years is 41.85M. The current 529.36M Enterprise Value has changed 126.38% with respect to the historical average. Over the past ten years (40 quarters), RLMD's Enterprise Value was at its highest in in the March 2026 quarter at 592.94M. The Enterprise Value was at its lowest in in the March 2023 quarter at -11888425.00.

Relmada Therapeutics, Inc. (RLMD) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Relmada Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Relmada Therapeutics, Inc. (RLMD) Average Enterprise Value

How has RLMD Enterprise Value performed in the past?

The current Enterprise Value of Relmada Therapeutics, Inc. (RLMD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Relmada Therapeutics, Inc. (RLMD) Enterprise Value vs. Peers

How is RLMD’s Enterprise Value compared to its peers?

Relmada Therapeutics, Inc.’s Enterprise Value is greater than Acrivon Therapeutics, Inc. Common Stock (29.56M), greater than PMV Pharmaceuticals, Inc. (18.23M), greater than Immunic, Inc. (-8447425.00), greater than TScan Therapeutics, Inc. (9.77M), greater than Vaxart, Inc. (73.40M), greater than Lite Strategy, Inc. (24.82M), greater than Fortress Biotech, Inc. (-90930109.00), greater than Repare Therapeutics Inc. (41.75M), greater than Cibus, Inc. (334.07M), greater than Adicet Bio, Inc. (55.24M),

Build a custom stock screener for Relmada Therapeutics, Inc. (RLMD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relmada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Relmada Therapeutics, Inc. (RLMD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Relmada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.